Fort Lauderdale, FL, May 07, 2018 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX: OMCM), a global provider of clinical data management technology, today announced the launch of OmniComm AutoEncoder, a user-friendly tool for coding clinical data against medical dictionaries. OmniComm will showcase and demonstrate AutoEncoder at industry events around the globe, including Innovation Forum Europe, June 7-8 in Bonn, DIA China in Beijing on May 23-25, and DIA 2018 in Boston on June 24-28.
“We have taken the opportunity to build a state-of-the-art coding tool from scratch,” said Keith Howells, OmniComm’s chief technology officer. “It has sophisticated algorithms, including language-sensitive search capabilities, and it features a fresh, intuitive and responsive user interface. Coding professionals are going to feel really at home with this product.”
Coding is a unique and necessary process required by regulators during clinical trials or when monitoring the safety of approved products. Regulatory agencies require that adverse events be coded against the MedDRA dictionary, and that medications be coded against the WHO Drug dictionary. The coding process is performed by specialist medical professionals, who must ensure consistent and accurate decisions based on the content of the source term, any relevant related data, and prior decisions for the trial or drug project.
The OmniComm AutoEncoder provides a modern and sophisticated tool for performing these coding activities. Out of the box, AutoEncoder is fully integrated with OmniComm’s TrialMaster® product for Electronic Data Capture, and its open interfaces also allow for integration with any third-party EDC or safety reporting system.
“We are confident that our cutting-edge coding solution will be well received by the industry,” said Stephen Johnson, president and CEO of OmniComm. “AutoEncoder deploys the latest in technology and intuitive design. We’ve leveraged our previous 10 years of experience offering coding solutions and aligned this new technology to match the changing industry regulations. The result is a functionally rich, easy-to-use, innovative solution that is fully integrated with our TrialMaster EDC solution and easily integrated with third-party EDC and safety systems.”
About OmniComm Systems, Inc.
OmniComm Systems provides a role in enhancing patient lives by shortening time to market of essential life-saving treatments. OmniComm Systems is dedicated to providing the latest eClinical technology enabling the world’s life science organizations to maximize the value of their clinical research investments. OmniComm’s solutions provide better trial oversight and study delivery, connecting patients to better healthcare. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information.
Trademarks
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post
OmniComm Systems, Inc.
+1.954.473.1254
KvanderPost@omnicomm.com
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.